You can buy or sell Pfenex and other stocks, options, ETFs, and crypto commission-free!
Pfenex Inc., also called Pfenex, is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. Read More The company was founded on November 19, 2009 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Seeking AlphaMar 11
Pfenex's (PFNX) CEO Eef Schimmelpennink on Q4 2018 Results - Earnings Call Transcript
Pfenex Inc. (NYSEMKT:PFNX) Q4 2018 Earnings Conference Call March 11, 2019 4:30 PM ET Company Participants Eef Schimmelpennink - President and CEO Susan Knudson - CFO Conference Call Participants Jason Butler - JMP Securities Andy Hsieh - William Blair Operator Greetings, ladies and gentlemen, and welcome to the Pfenex Fourth Quarter and Fiscal Year-end 2018 Results and Business Update Cal. A Brief question-and-answer session will follow the formal presentation. As a reminder, this conference is bei...
Pfenex (NYSE:PFNX) - Q4 Earnings Outlook For Pfenex
Pfenex (NYSE: PFNX) releases its next round of earnings this Monday, Mar. 11. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report. Earnings and Revenue Wall Street analysts see Pfenex reporting a loss of 35 cents per share on revenue of $4.4 million. In the same quarter last year, Pfenex announced EPS of 23 cents on revenue of $17.9 million. Revenue would have fallen 75.43 percent from the same quarter last year. The company's reported EPS has stacked up against a...
Stock Price, News, & Analysis for Pfenex
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The c...
-$0.35 per share
-$0.22 per share